An international multicentre controlled clinical trial to evaluate high dose RIFApentine and a QUINolone [moxifloxacin] in the treatment of pulmonary tuberculosis.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Moxifloxacin (Primary) ; Rifapentine (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin
Indications Pulmonary tuberculosis
Focus Adverse reactions; Therapeutic Use
Acronyms RIFAQUIN

22 Feb 2023 Results(n=711) of pooled analysis from four Phase 3 clinical trials (OFLOTUB NCT00216385, REMoxTB NCT00864383, RIFAQUIN ISRCTN44153044, S31/A5349 NCT02410772) assessing Tb Outcomes in People Living with Hiv presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
06 Mar 2013 Primary endpoint 'Clinical-response-rate' has been met.
06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com